6QC Stock Chart & Stats
€15.70
-€0.50(-2.48%)
At close: 4:00 PM EST
€15.70
-€0.50(-2.48%)
Day’s Range― - ―
52-Week Range€15.20 - €23.60
Previous CloseN/A
Volume0.00
Average Volume (3M)0.00
Market Cap
€969.77M
Enterprise Value€375.50K
Total Cash (Recent Filing)€42.23B
Total Debt (Recent Filing)€229.93B
Price to Earnings (P/E)21.1
Beta0.40
Next Earnings
Nov 16, 2026EPS Estimate
0.57Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)167.96
Shares Outstanding51,516,000
10 Day Avg. Volume0
30 Day Avg. Volume0
Financial Highlights & Ratios
PEG Ratio-0.52
Price to Book (P/B)1.11
Price to Sales (P/S)0.72
P/FCF Ratio24.19
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)2.51
Revenue Forecast (FY)€1.65B
Bulls Say, Bears Say
Bulls Say
Revenue GrowthTTM revenue grew strongly (+2.276) while the company serves Japan’s generic-drug market, indicating continued demand for its portfolio. Persistent top-line expansion can support manufacturing scale, fund product development, and preserve commercial relevance over the next several quarters even as earnings fluctuate.
Stable Gross MarginA gross margin of roughly 36% has remained steady despite continued business expansion, suggesting that core pricing and production economics have been relatively resilient. This stability provides a foundation for recovery if operating execution improves and helps protect the economics of the generic portfolio.
Broad Generic Drug PortfolioA broad portfolio spanning multiple therapeutic areas supports diversified participation in Japan’s healthcare market rather than reliance on one medicine or treatment category. Its generic focus also aligns with cost-effective care and ongoing substitution from branded drugs after patent expiry, supporting durable demand.
Bears Say
Compressed ProfitabilityProfitability has weakened materially even while revenue continues to grow, with TTM net and EBIT margins well below prior-year levels. This compression reduces the earnings benefit of scale, limits internally funded investment, and leaves future results more sensitive to cost control and operating execution.
Elevated LeverageDebt has increased substantially and leverage is now elevated relative to equity, while ROE has fallen to about 2.9%. A more burdened balance sheet can constrain financial flexibility, increase the importance of stable cash generation, and limit the company’s ability to fund growth or absorb weaker profitability.
Thin, Volatile Free Cash FlowFree cash flow is both thin and volatile, and only about 0.27 of reported net income converted into free cash flow in the TTM period. Weak cash conversion reduces surplus funds available for debt reduction, product investment, and shareholder returns, increasing execution risk over coming quarters.
Towa Pharmaceutical Co News
6QC FAQ
What was Towa Pharmaceutical Co Ltd’s price range in the past 12 months?
Towa Pharmaceutical Co Ltd lowest stock price was €15.20 and its highest was €23.60 in the past 12 months.
What is Towa Pharmaceutical Co Ltd’s market cap?
Towa Pharmaceutical Co Ltd’s market cap is €969.77M.
When is Towa Pharmaceutical Co Ltd’s upcoming earnings report date?
Towa Pharmaceutical Co Ltd’s upcoming earnings report date is Nov 16, 2026 which is in 62 days.
How were Towa Pharmaceutical Co Ltd’s earnings last quarter?
Towa Pharmaceutical Co Ltd released its earnings results on Aug 06, 2026. The company reported €0.629 earnings per share for the quarter.
Is Towa Pharmaceutical Co Ltd overvalued?
According to Wall Street analysts Towa Pharmaceutical Co Ltd’s price is currently Overvalued.
Does Towa Pharmaceutical Co Ltd pay dividends?
Towa Pharmaceutical Co Ltd does not currently pay dividends.
What is Towa Pharmaceutical Co Ltd’s EPS estimate?
Towa Pharmaceutical Co Ltd’s EPS estimate is 0.57.
How many shares outstanding does Towa Pharmaceutical Co Ltd have?
Towa Pharmaceutical Co Ltd has 51,516,000 shares outstanding.
What happened to Towa Pharmaceutical Co Ltd’s price movement after its last earnings report?
Towa Pharmaceutical Co Ltd reported an EPS of €0.629 in its last earnings report. Following the earnings report the stock price went up 1.923%.
Which hedge fund is a major shareholder of Towa Pharmaceutical Co Ltd?
Currently, no hedge funds are holding shares in DE:6QC
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Towa Pharmaceutical Co Ltd
Towa Pharmaceutical Co., Ltd., along with its subsidiaries, is actively engaged in the entire pharmaceutical lifecycle within Japan, from researching and developing to manufacturing and marketing prescription medications, active pharmaceutical ingredients, and intermediate compounds. The company's extensive product offerings target critical therapeutic areas, including diabetes, digestive and nervous system disorders, and allergic conditions. Furthermore, their portfolio encompasses vitamins, antibiotics, and oncology treatments. With a comprehensive collection of approximately 700 distinct drug products, Towa Pharmaceutical Co., Ltd. was founded in 1951 and is headquartered in Osaka, Japan.
Technical Analysis
Kaken Pharmaceutical Co
―
Kissei Pharmaceutical Co
―
Mochida Pharmaceutical Co., Ltd.
―
KYORIN Pharmaceutical Co.,Ltd.
―
SAWAI GROUP HOLDINGS Co., Ltd.
―